Teresa Carvalho, MS, science writer —

Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.

Articles by Teresa Carvalho

Triple Therapy Effective in AAV Relapse After Kidney Transplant

A combination of rituximab, prednisone, and tacrolimus effectively treated a recurrence of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) after a kidney transplant, a case study reported. The case highlights the importance of closely monitoring AAV patients on immunosuppressive therapy with belatacept, particularly when a kidney injury follows a kidney…

AstraZeneca COVID-19 Vaccine Tied to AAV-related Kidney Damage

The AstraZeneca COVID-19 vaccine may have triggered kidney inflammation linked to ANCA-associated vasculitis (AAV) in a 51-year-old woman, according to a case report. “Due to the temporal association between the application of ChAdOx1 nCoV-19 vaccine and the onset of renal [kidney] function decline in a previously healthy patient, it…

COVID-19 Suspected Cause of Girl’s ANCA-associated Vasculitis

A 16-year-old girl developed granulomatosis with polyangiitis (GPA), a type of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), after being infected with SARS-COV-2, the virus that causes COVID-19, according to a recent case report. Hers is the fourth known case of pediatric-onset AAV following COVID-19 infection, suggesting the virus could…

#RAREis Representation Program Promotes Equity, Diversity

Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…